A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma

BACKGROUND: To evaluate the impact of treatment on health states that affect patients’ quality of life in advanced follicular lymphoma. METHODS: A quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TwiST) analysis was performed on data from a phase III clinical trial (Marc...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcus, R, Aultman, R, Jost, F
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813752/
https://www.ncbi.nlm.nih.gov/pubmed/19920818
http://dx.doi.org/10.1038/sj.bjc.6605443
_version_ 1782176953787219968
author Marcus, R
Aultman, R
Jost, F
author_facet Marcus, R
Aultman, R
Jost, F
author_sort Marcus, R
collection PubMed
description BACKGROUND: To evaluate the impact of treatment on health states that affect patients’ quality of life in advanced follicular lymphoma. METHODS: A quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TwiST) analysis was performed on data from a phase III clinical trial (Marcus et al, 2008). RESULTS: Cyclophosphamide, vincristine, and prednisone plus rituximab (R-CVP)-treated patients gained a mean of 15.17 months in TWiST, 8.33 months in Q-TwiST, and 11.30 months less in disease relapse, without increase in toxicity compared with cyclophosphamide, vincristine, and prednisone (CVP)-treated patients. CONCLUSION: Rituximab plus CVP-treated patients reached a significant and clinically meaningful improvement within 12 months in quality-adjusted survival compared with CVP.
format Text
id pubmed-2813752
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-28137522011-01-05 A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma Marcus, R Aultman, R Jost, F Br J Cancer Short Communication BACKGROUND: To evaluate the impact of treatment on health states that affect patients’ quality of life in advanced follicular lymphoma. METHODS: A quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TwiST) analysis was performed on data from a phase III clinical trial (Marcus et al, 2008). RESULTS: Cyclophosphamide, vincristine, and prednisone plus rituximab (R-CVP)-treated patients gained a mean of 15.17 months in TWiST, 8.33 months in Q-TwiST, and 11.30 months less in disease relapse, without increase in toxicity compared with cyclophosphamide, vincristine, and prednisone (CVP)-treated patients. CONCLUSION: Rituximab plus CVP-treated patients reached a significant and clinically meaningful improvement within 12 months in quality-adjusted survival compared with CVP. Nature Publishing Group 2010-01-05 2009-11-17 /pmc/articles/PMC2813752/ /pubmed/19920818 http://dx.doi.org/10.1038/sj.bjc.6605443 Text en Copyright © 2010 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Short Communication
Marcus, R
Aultman, R
Jost, F
A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma
title A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma
title_full A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma
title_fullStr A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma
title_full_unstemmed A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma
title_short A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma
title_sort quality-adjusted survival analysis (q-twist) of rituximab plus cvp vs cvp alone in first-line treatment of advanced follicular non-hodgkin's lymphoma
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813752/
https://www.ncbi.nlm.nih.gov/pubmed/19920818
http://dx.doi.org/10.1038/sj.bjc.6605443
work_keys_str_mv AT marcusr aqualityadjustedsurvivalanalysisqtwistofrituximabpluscvpvscvpaloneinfirstlinetreatmentofadvancedfollicularnonhodgkinslymphoma
AT aultmanr aqualityadjustedsurvivalanalysisqtwistofrituximabpluscvpvscvpaloneinfirstlinetreatmentofadvancedfollicularnonhodgkinslymphoma
AT jostf aqualityadjustedsurvivalanalysisqtwistofrituximabpluscvpvscvpaloneinfirstlinetreatmentofadvancedfollicularnonhodgkinslymphoma
AT marcusr qualityadjustedsurvivalanalysisqtwistofrituximabpluscvpvscvpaloneinfirstlinetreatmentofadvancedfollicularnonhodgkinslymphoma
AT aultmanr qualityadjustedsurvivalanalysisqtwistofrituximabpluscvpvscvpaloneinfirstlinetreatmentofadvancedfollicularnonhodgkinslymphoma
AT jostf qualityadjustedsurvivalanalysisqtwistofrituximabpluscvpvscvpaloneinfirstlinetreatmentofadvancedfollicularnonhodgkinslymphoma

Ejemplares similares